These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
112 related items for PubMed ID: 6891821
41. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia. Koller W, Curtin J, Fields J. Neuropharmacology; 1984 Oct; 23(10):1191-4. PubMed ID: 6240609 [Abstract] [Full Text] [Related]
43. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. Miller DD, Eudicone JM, Pikalov A, Kim E. J Clin Psychiatry; 2007 Dec; 68(12):1901-6. PubMed ID: 18162021 [Abstract] [Full Text] [Related]
46. Estradiol can suppress haloperidol-induced supersensitivity in dyskinetic monkeys. Bédard PJ, Boucher R. Neurosci Lett; 1986 Feb 28; 64(2):206-10. PubMed ID: 3960400 [Abstract] [Full Text] [Related]
47. Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Halliday GM, Pond SM, Cartwright H, McRitchie DA, Castagnoli N, Van der Schyf CJ. Exp Neurol; 1999 Jul 28; 158(1):155-63. PubMed ID: 10448427 [Abstract] [Full Text] [Related]
48. Tardive dyskinesia: are first signs reversible? Quitkin F, Rifkin A, Gochfeld L, Klein DF. Am J Psychiatry; 1977 Jan 28; 134(1):84-7. PubMed ID: 12666 [Abstract] [Full Text] [Related]
49. Physiological doses of estradiol can increase lingual dyskinesia and cerebrospinal fluid homovanillic acid in monkeys. Bédard PJ, Boucher R, Daigle M, Di Paolo T. Neurosci Lett; 1985 Aug 05; 58(3):327-31. PubMed ID: 2995879 [Abstract] [Full Text] [Related]
50. Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia. Nevet A, Morris G, Saban G, Fainstein N, Bergman H. J Neurophysiol; 2004 Oct 05; 92(4):1973-81. PubMed ID: 15115785 [Abstract] [Full Text] [Related]
51. Tardive dyskinesia, fluphenazine decanoate, and haloperidol. Waddington JL. Am J Psychiatry; 1982 May 05; 139(5):703-4. PubMed ID: 7072867 [No Abstract] [Full Text] [Related]
54. Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol. Lublin H, Gerlach J. Eur J Pharmacol; 1988 Aug 24; 153(2-3):239-45. PubMed ID: 3263277 [Abstract] [Full Text] [Related]
55. Biphasic and long-lasting effect of ceruletide on tardive dyskinesia. Nishikawa T, Tanaka M, Koga I, Uchida Y. Psychopharmacology (Berl); 1985 Aug 24; 86(1-2):43-4. PubMed ID: 3927366 [Abstract] [Full Text] [Related]
57. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Egan MF, Hurd Y, Ferguson J, Bachus SE, Hamid EH, Hyde TM. Psychopharmacology (Berl); 1996 Oct 24; 127(4):337-45. PubMed ID: 8923569 [Abstract] [Full Text] [Related]
58. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Hashimoto T, Ross DE, Gao XM, Medoff DR, Tamminga CA. Psychopharmacology (Berl); 1998 May 24; 137(2):107-12. PubMed ID: 9629996 [Abstract] [Full Text] [Related]
59. Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Stein MH. Am J Psychiatry; 1991 May 24; 148(5):683. PubMed ID: 2018175 [No Abstract] [Full Text] [Related]